Abstract
The results of previous work performed in our laboratory using an in situ perfusion technique in rats and rabbit apical brush border membrane vesicles have suggested that the intestinal uptake of valacyclovir (VACV) appears to be mediated by multiple membrane transporters. Using these techniques, it is difficult to characterize the transport kinetics of VACV with each individual transporter in the presence of multiple known or unknown transporters. The purpose of this study was to characterize the interaction of VACV and the human intestinal peptide transporter using Chinese hamster ovary (CHO) cells that overexpress the human intestinal peptide transporter (hPEPT1) gene. VACV uptake was significantly greater in CHO cells transfected with hPEPT1 than in cells transfected with only the vector, pcDNA3. The optimum pH for VACV uptake was determined to occur at pH 7.5. Proton cotransport was not observed in hPEPT1/CHO cells, consistent with previously observed results in tissues and Caco-2 cells. VACV uptake was concentration dependent and saturable with a Michaelis-Menten constant and maximum velocity of 1.64 ± 0.06 mM and 23.34 ± 0.36 nmol/mg protein/5 min, respectively. A very similarKm value was obtained in hPEPT1/CHO cells and in rat and rabbit tissues and Caco-2 cells, suggesting that hPEPT1 dominates the intestinal transport properties of VACV in vitro. VACV uptake was markedly inhibited by various dipeptides and β-lactam antibiotics, and Ki values of 12.8 ± 2.7 and 9.1 ± 1.2 mM were obtained for Gly-Sar and cefadroxil at pH 7.5, respectively. The present results demonstrate that VACV is a substrate for the human intestinal peptide transporter in hPEPT1/CHO cells and that although transport is pH dependent, proton cotransport is not apparent. Also, the results demonstrate that the hPEPT1/CHO cell system has use in investigating the transport kinetics of drugs with the human intestinal peptide transporter hPEPT1; however, the extrapolation of these transport properties to the in vivo situation requires further investigation.
Footnotes
-
Send reprint requests to: Prof. Patrick J. Sinko, Department of Pharmaceutics, College of Pharmacy, Rutgers University, 160 Frelinghuysen Rd., Piscataway, NJ 08854. E-mail:sinko{at}rci.rutgers.edu
-
↵1 This work was supported in part by National Institutes of Health Grants AI33789 and AI42007.
-
↵2 Present address: Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta, GA 30912.
- Abbreviations:
- ACV
- acyclovir
- BBMV
- brush border membrane vesicle
- CHO
- Chinese hamster ovary
- VACV
- valacyclovir
- XLO
- Xenopus laevis oocytes
- Received June 25, 1998.
- Accepted November 2, 1998.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
Log in using your username and password
Purchase access
In this issue
Interactions of a Nonpeptidic Drug, Valacyclovir, with the Human Intestinal Peptide Transporter (hPEPT1) Expressed in a Mammalian Cell Line
